David Davies

Ph.D., Head of Drug Discovery, has over 25 years of experience in medicinal chemistry within the pharmaceutical industry (GSK), most of which were dedicated to the development of antibiotic drugs for clinical use and biodefense. David has also worked with biotech companies in support of their strategy and medicinal chemistry efforts. He is an inventor on about 25 patents, most of them in the antibacterial area.  His antibacterial projects were supported by the Welcome Trust and the DTRA (US Defense Threat Reduction Agency).

Jérôme Castandet

Ph.D., is a biologist with extensive experience in antibacterial drug discovery, from assay development to lead optimization. As the leader of a microbiology team in the Department of Infectious Diseases at Sanofi-Aventis R&D (Toulouse/Labège, France), Jérôme managed the in vitro biology aspects of different antibacterial discovery programs. Jérôme holds a PhD in Microbiology from the University of Toulouse and is the author of several peer-reviewed publications in the area of microbiology and immunology.

Alicia Coelho

Ph.D., microbiologist, has dedicated her career to research on clinical multidrug-resistant pathogens and nosocomial infections. Alicia worked in the Microbiology research team of the Vall d’Hebron University Hospital in Barcelona (Spain) where she developed expertise in antimicrobial resistance, clinical diagnostic and bacterial genetics. Alicia holds a PhD in Microbiology from the Autonomous University of Barcelona and is the author of several scientific publications in the area of clinical microbiology and antimicrobial chemotherapy